Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy

被引：2

作者：

Chung, Eric M. ^{[1
,2
]}

Lu, Diana J. ^{[1
,2
]}

Nguyen, Anthony T. ^{[1
,2
]}

Hendifar, Andrew E. ^{[2
]}

Nissen, Nicholas N. ^{[2
,3
]}

Gong, Jun ^{[2
]}

Osipov, Arsen ^{[2
]}

Gangi, Alexandra ^{[2
]}

Attiyeh, Marc A. ^{[2
]}

Atkins, Katelyn M. ^{[1
,2
]}

Kamrava, Mitchell ^{[1
,2
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA

[2] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[3] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA USA

来源：

ADVANCES IN RADIATION ONCOLOGY | 2024年 / 9卷 / 05期

关键词：

INDUCTION CHEMOTHERAPY; RADIOTHERAPY; GEMCITABINE; TRIAL; RESECTION; 5-FLUOROURACIL; FOLFIRINOX;

D O I：

10.1016/j.adro.2024.101471

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The role of preoperative stereotactic body radiation therapy (SBRT) in pancreatic cancer is controversial, and questions regarding the optimal dose and radiation treatment fi eld remain. To better inform future investigations of SBRT dose and radiation fi elds, we evaluated the patterns of failure in patients with borderline resectable/locally advanced pancreatic cancer (BR/LAPC) after preoperative chemotherapy and SBRT in patients who underwent surgical resection. Methods and Materials: We performed a single -institution retrospective review of consecutive patients treated from September 2017 to January 2022 with BR/LAPC. Patients who underwent preoperative chemotherapy and SBRT followed by surgical resection were reviewed. SBRT was delivered to a dose of 33 Gy in 5 fractions. Kaplan - Meier overall survival and progression -free survival estimates were calculated. Results: In total, 18 patients (12 BRPC, 6 LAPC) were included. Median age was 69 years (range 41-84 years). Median follow-up was 30 months (range 13-59 months). Seventeen patients (94%) had a R0 resection and 13 (72%) underwent vascular reconstruction. Median overall survival and progression -free survival was 42 months (range 13-59 months) and 23 months (range 1-45 months), respectively. In total, 61% (11/18) patients experienced progression at any point during follow-up. Of the patients who experienced recurrence, 27% (3/11) experienced local progression as component of their fi rst recurrence, whereas 100% (11/11) experienced distant progression as a component of their fi rst recurrence. When examining all recurrences that occurred at any point in follow-up, 28% (5/18) of patients experienced local or locoregional recurrence and 61% (11/18) experienced distant progression. Conclusions: Local control and margin negative resection rates were excellent with preoperative chemotherapy and nondose-escalated SBRT in surgically resected patients with BR/LAPC. Distant recurrence was the predominant site of failure with lower incidences of isolated locoregional recurrences. Additional research is needed to determine the ideal treatment volume and patients who may bene fi t from dose escalation. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页数：8

共 41 条

[41] Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design [J].

Zhu, Xiaofei ;

Ju, Xiaoping ;

Cao, Yangsen ;

Shen, Yuxin ;

Cao, Fei ;

Qing, Shuiwang ;

Fang, Fang ;

Jia, Zhen ;

Zhang, Huojun .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01) :101-110

← 1 2 3 4 5 →